Boundless Bio, Inc. financial data

Symbol
BOLD on Nasdaq
Industry
Pharmaceutical Preparations
Location
10955 Alexandria Way, Suite 100, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.64K %
Return On Equity -73.9 % -264%
Return On Assets -38.1 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 22.3M shares +0.2%
Common Stock, Shares, Outstanding 22.3K shares -98.2%
Entity Public Float 68.4M USD
Common Stock, Value, Issued 2K USD
Weighted Average Number of Shares Outstanding, Basic 17M shares +1297%
Weighted Average Number of Shares Outstanding, Diluted 17M shares +1297%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 55.3M USD +29.6%
General and Administrative Expense 18M USD +48%
Operating Income (Loss) -73.3M USD -33.7%
Nonoperating Income (Expense) 7.9M USD +47.4%
Net Income (Loss) Attributable to Parent -65.4M USD -32.2%
Earnings Per Share, Basic -3.85 USD/shares +90.5%
Earnings Per Share, Diluted -3.85 USD/shares +90.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 26.6M USD +12.2%
Cash, Cash Equivalents, and Short-term Investments 152M USD
Assets, Current 154M USD +24.3%
Property, Plant and Equipment, Net 4.32M USD +67.9%
Operating Lease, Right-of-Use Asset 47M USD +2250%
Assets 206M USD +58.9%
Accounts Payable, Current 1.27M USD -42.7%
Employee-related Liabilities, Current 2.78M USD -4.04%
Liabilities, Current 8.14M USD -13.1%
Operating Lease, Liability, Noncurrent 47.6M USD
Liabilities 55.8M USD +496%
Accumulated Other Comprehensive Income (Loss), Net of Tax 121K USD +203%
Retained Earnings (Accumulated Deficit) -201M USD -48%
Stockholders' Equity Attributable to Parent 151M USD
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 151M USD
Liabilities and Equity 206M USD +58.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -15.8M USD -30.5%
Net Cash Provided by (Used in) Financing Activities -924K USD -3081%
Net Cash Provided by (Used in) Investing Activities 18.1M USD -18.2%
Common Stock, Shares Authorized 700M shares
Common Stock, Shares, Issued 22.3K shares -98.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 1.44M USD -85.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 27.1M USD +11.9%
Deferred Tax Assets, Valuation Allowance 58.8M USD +53.5%
Deferred Tax Assets, Gross 72.1M USD +84.9%
Depreciation 263K USD +11%
Payments to Acquire Property, Plant, and Equipment 83K USD -3.49%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -65.3M USD -33.2%
Property, Plant and Equipment, Gross 8.03M USD +51.5%
Operating Lease, Liability, Current 121K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Deferred Tax Assets, Operating Loss Carryforwards 27.6M USD +50.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 70M shares
Unrecognized Tax Benefits 9.21M USD +14.5%
Operating Lease, Payments 700K USD 0%
Additional Paid in Capital 352M USD +3817%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 13.3M USD +1844%
Share-based Payment Arrangement, Expense 7.52M USD +125%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%